Finance
Enzyme company completes $9.2 million financing
Published in Gene Therapy Weekly, March 4th, 2004
The financing also included an option to purchase an additional $15.9 million in warrants callable by Hyalozyme. Ritchie Capital, Cimarron Biomedical Investors, and Colt Ventures participated in the round. Brean Murray & Co., Inc., acted as placement agent. Kirkpatrick & Lockhart, LLP, acted as counsel to Grove Capital.
"Hyalozyme has successfully developed a recombinant human enzyme product that will dramatically improve current treatment options in the therapeutic areas of infertility, ophthalmology, and oncology," said Peter G. Geddes of Grove Capital. "The...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-03-04)
More Articles from Gene Therapy Weekly
- Adverse Drug Effects
Germline transfection is possible after intramyocardial gene delivery - Cancer Therapy
The ZD55-gene therapy system is a potent anticancer tool - Autoimmune Disease
Hepatocyte growth factor prevents and ameliorates scleroderma symptoms - Colon Cancer
A dominant-negative mutant of the c-Jun gene stems colorectal cancer growth - Oncology
5-Fluorocytosine increases the toxicity of oncolytic viruses - Stem-Cell Research
Electroporation augments the transfection of marrow stromal cells - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
